Journal of Clinical Endocrinology & Metabolism, Vol 81, 3265-3269, Copyright © 1996 by Endocrine Society

ARTICLES

Endocrine and metabolic effects of interferon-alpha in humans

EP Corssmit, R Heijligenberg, E Endert, MT Ackermans, HP Sauerwein and JA Romijn
Department of Internal Medicine, University of Amsterdam, The Netherlands.

Interferon-alpha (IFN alpha) concentrations are increased in conditions associated with tissue injury. To investigate the endocrine and metabolic actions of IFN alpha in vivo, we studied eight healthy controls on two occasions, once after administration of 5 million units/m2 rhIFN alpha and once after administration of saline (control). Rates of appearance (Ra) of glucose and glycerol in plasma were measured by infusion of [3-3H]glucose and D5-glycerol, respectively. Energy expenditure and substrate oxidation were determined by indirect calorimetry. IFN alpha induced increases in plasma concentrations of norepinephrine (225 +/- 93%; P < 0.02 vs. control), epinephrine (272 +/- 80%; P < 0.05), cortisol (353 +/- 63%; P < 0.02), glucagon (50 +/- 12%; P < 0.05), free fatty acids (223 +/- 61%; P < 0.02), and glycerol (68 +/- 21%; P < 0.02) and in resting energy expenditure (36 +/- 50%; P < 0.03). The Ra of glycerol (169 +/- 39%; P < 0.02) and fat oxidation (104 +/- 23%, P < 0.02) were also increased after IFN alpha treatment. The Ra of glucose was higher at the end of the recombinant human IFN alpha treatment day than in the control experiment (12.83 +/- 1.08 vs. 9.34 +/- 0.46 mumol/kg.min; P < 0.03). It is concluded that IFN alpha administration induces, directly or indirectly, major endocrine and metabolic changes and is probably part of the cytokine network mediating the endocrine and catabolic reactions to tissue injury.

This article has been cited by other articles:

				J. de Metz, J. A. Romijn, E. Endert, M. T. Ackermans, G. J. Weverling, O. R. Busch, L. Th. de Wit, D. J. Gouma, I. J. M. t. Berge, and H. P. Sauerwein Interferon-{gamma} increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients J Appl Physiol, February 1, 2004; 96(2): 597 - 603. [Abstract] [Full Text] [PDF]

				H. Ruan, N. Hacohen, T. R. Golub, L. Van Parijs, and H. F. Lodish Tumor Necrosis Factor-{alpha} Suppresses Adipocyte-Specific Genes and Activates Expression of Preadipocyte Genes in 3T3-L1 Adipocytes: Nuclear Factor-{kappa}B Activation by TNF-{alpha} Is Obligatory Diabetes, May 1, 2002; 51(5): 1319 - 1336. [Abstract] [Full Text] [PDF]

				M. A. COOPER and E. C. RITCHIE Testosterone Replacement Therapy for Anxiety Am J Psychiatry, November 1, 2000; 157(11): 1884 - 1884. [Full Text]

				E. Dieperink, M. Willenbring, and S. B. Ho Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review Am J Psychiatry, June 1, 2000; 157(6): 867 - 876. [Abstract] [Full Text]

				J. de Metz, F. Sprangers, E. Endert, M. T. Ackermans, I. J. M. ten Berge, H. P. Sauerwein, and J. A. Romijn Interferon-gamma has immunomodulatory effects with minor endocrine and metabolic effects in humans J Appl Physiol, February 1, 1999; 86(2): 517 - 522. [Abstract] [Full Text] [PDF]

				R. G. Maunder, J. J. Hunter, and S. V. Feinman Interferon Treatment of Hepatitis C Associated With Symptoms of PTSD Psychosomatics, October 1, 1998; 39(5): 461 - 464. [Full Text]

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]